HBAN — Huntington Bancshares Incorporated

Price action, not analyst ratings, sets the tone: as of 2026-10-04 HBAN is down 9.18% over one month and 14.17% over three months, sitting just above its 52-week low of $14.82 with RSI at 33.94 - a near-oversold downtrend. The trigger was management's September 2026 Barclays conference cut to its 2027 adjusted EPS target ($1.75-$1.83 from $1.90-$1.93) and a slower margin-expansion path, which prompted target trims (JPMorgan to $17.50, Truist to $19.00). Sell-side remains more constructive than the tape - consensus 'Moderate Buy/Hold' with an average target near $19.63-$20 - so there's real daylight between price and rating.

Revenue is accelerating hard but mostly inorganically: Q2 2026 revenue of $4,167M was +37.7% YoY vs $3,027M in Q2 2025, and jumped sequentially from $3,247M in Q4 2025 to $3,768M in Q1 2026 to $4,167M in Q2 2026 as the Cadence/Veritex footprint was absorbed (total assets leapt from ~$210B to ~$285B between Q3 2025 and Q1 2026). Earnings haven't kept pace per-share: Q2 2026 net income of $727M was +35.6% YoY, but diluted EPS was only $0.38 vs $0.34 (+11.8%) because share count rose with the deal, and Q1 2026 EPS was a soft $0.25 - likely integration charges. Operating margin is roughly flat, not expanding: 21.5% in Q2 2026 vs 21.1% in Q2 2025, after dipping to 17.0% in Q1 2026. Net read: top-line inflecting up on acquisitions, per-share earnings growing only mid-single-digits, margins stable - and Q1 2026 looks like a blip (deal charges), not a structural break. The whole thesis now hinges on whether $365M of Cadence run-rate cost savings actually show up in 2027 margins.

Cheap-to-fair, and cheap against its own history. As of 2026-10-04 the stock trades at 11.27x TTM EPS ($1.232) vs a 5-year average P/E of 12.41x, and at 2.15x sales vs a 5-year average of 2.30x - both a modest discount. More striking is 0.914x price-to-book (BVPS ≈ $16.15 on $32.6B equity), i.e. below liquidation-ish book value for a bank earning ~9.1% ROE. Forward P/E on the $1.353 next-FY estimate is ~11.3x, with the PEG ratio meaningless here (the reported value is a broken negative). The 3.9% dividend yield anchors the downside. This is not a screaming bargain - a bank earning 9% ROE arguably deserves ~0.9-1.0x book - but it is priced for continued disappointment, not for success.

The market is pricing in the guidance cut and a slower NIM recovery, not future improvement. At ~11.3x forward EPS and sub-book, there is little embedded growth expectation: the multiple already discounts flat-to-modest EPS. That creates an asymmetric setup - if Cadence synergies and a stabilizing deposit beta let EPS re-accelerate toward the 2027 adjusted target ($1.75-$1.83), even a re-rating back to the 5-year 12.4x average implies meaningful upside. Conversely, if credit costs keep rising and NIM stays pressured, the stock has a legitimate floor argument near book (~$16), but a cheap multiple on repeatedly-cut estimates is a value trap, not a value play. Watch Q3 results on 2026-10-22 for signs guidance has finally stopped falling.

Unambiguously bearish trend as of 2026-10-04. RSI(14) was 33.94 - approaching but not yet at oversold - and price sat below every major average: -4.04% vs the 20-day, -8.46% vs the 50-day, and -9.4% vs the 200-day, with the 52-week low of $14.82 just below spot. Momentum is negative across horizons (-1.98% 1-week, -9.18% 1-month, -14.17% 3-month), though the -2.91% 6-month figure shows the damage is recent and concentrated in the last quarter. Entry-timing implication: this is a downtrend with no confirmed bottom; a contrarian can start scaling in near the $14.82-$15.50 zone, but the cleaner signal is a reclaim of the 20-day average and an RSI turn back above 40-45. Do not confuse 'cheap and oversold' with 'bottomed.'

• Higher-for-longer rates cut both ways for regional banks: asset yields expand, but elevated deposit costs and rising deposit beta keep compressing net interest margin - the core reason management trimmed its margin-expansion path.
• Credit normalization is the quiet risk: provisions for credit losses rose YoY in recent quarters, and any CRE or consumer deterioration would hit a bank already earning a modest ~9% ROE.
• Regional-bank sector sentiment remains structurally cautious post-2023, keeping the whole group discounted to book and amplifying reactions to guidance changes.
• Regulatory/capital backdrop: solid CCAR stress-test outcomes support buybacks (~$1.3-1.4B anticipated for 2027) and the dividend, but elevated compliance and operational-risk costs are a persistent expense drag.
• Consolidation wave: HBAN is a consolidator (Cadence, Veritex), which boosts scale and revenue but loads integration and execution risk onto a compressed valuation.

• Q3 2026 earnings on 2026-10-22 - the key test of whether NIM, credit, and guidance have stabilized.
• Realization of ~$365M in annualized Cadence cost synergies and completion of system conversions feeding into 2027 margin.
• Capital return: ~$1.3-1.4B of anticipated 2027 share repurchases plus the ~4% dividend.
• Digital/fee-income build-out under new marketing and digital leadership, plus the new President appointment (Brant Standridge) in September 2026.
• Any turn toward Fed rate cuts, which would ease deposit costs and aid NIM recovery.

• Further downward guidance revisions - the September 2026 cut to $1.75-$1.83 for 2027 is fresh, and estimates may not have fully reset.
• Deposit-cost/NIM pressure persisting if rates stay higher for longer, delaying the margin recovery the multiple assumes.
• Credit deterioration - rising provisions and any CRE/consumer stress could force reserve builds that eat into an already marginal ROE.
• Integration/execution risk on Cadence and Veritex; missed synergy targets would undermine the growth story.
• Value-trap risk: at 0.91x book the stock is cheap, but a bank stuck at ~9% ROE may deserve to stay cheap.

HBAN is a legitimately cheap, well-capitalized regional bank - 0.91x book, 11.3x forward earnings, 3.9% dividend, negative accruals (quality earnings), and a 94/100 growth score in the deterministic model - but the forward story just got shakier with the September 2026 2027 EPS cut, and the tape is in a clear downtrend near 52-week lows. I would treat it as a patient value/income position, not a momentum buy: the risk/reward skews positive for a 12-18 month holder willing to tolerate more weakness toward $15 (or book at ~$16), but there is no near-term catalyst to force a re-rating until Q3 numbers on 2026-10-22 prove NIM and credit are stabilizing.

Blended approach: ~12.5x forward EPS of $1.353 (just above the 5-year average P/E of 12.41, reflecting post-Cadence scale but tempering for the guidance cut) gives ~$16.90, and ~1.05x book value per share of ~$16.15 (a slight premium justified by ROE trending from 9.1% toward ~10.5% as synergies land) gives ~$16.95; cross-checking against management's 2027 adjusted EPS guide of $1.75-$1.83 at a conservative ~10x supports the upper teens, so I settle at $17.50.